secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-09-19T23:59:59+00:00
Accession:  0001193125-22-246740
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller
-------------------------------------------------------------------------------

- Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.
- Jones previously CFO at LogicBio; 10+ years at Biogen in various finance roles including VP of R&D and BD finance.
- Compensation: $475k base salary, 45% target annual bonus, $1.875M stock option, $625k RSUs, $300k PSUs.
- Stock option vests: 25% on first anniversary, then monthly through year 4; RSUs vest equally over 3 years.
- Company highlights PYRUKYND commercial launch and five pivotal trials; Jones to lead financial strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/0001193125-22-246740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522246740/d367124d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-246740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer